Vertex Pharmaceuticals (VRTX) Interest Expenses (2009 - 2025)

Vertex Pharmaceuticals has reported Interest Expenses for 10 years, with the latest figure at $3.3 million in Q4 2025.

• For the quarter ending Q4 2025, Interest Expenses rose 17.86% year-over-year to $3.3 million; the trailing twelve-month figure through Mar 2026 stood at $10.3 million (down 55.6% YoY), and the FY2025 full-year result was $13.3 million, down 56.54% from the prior year.
• Interest Expenses for Q4 2025 stood at $3.3 million, roughly flat from $3.3 million in the prior quarter.
• The five-year high for Interest Expenses was $11.2 million in Q2 2023, with the low at $2.8 million in Q4 2024.
• Average Interest Expenses over 3 years is $7.0 million, with a median of $7.5 million recorded in 2024.
• Year-over-year, Interest Expenses tumbled 73.58% in 2024 and grew 17.86% in 2025.
• Tracing VRTX's Interest Expenses over 3 years: stood at $10.6 million in 2023, then plunged by 73.58% to $2.8 million in 2024, then advanced by 17.86% to $3.3 million in 2025.
• The last three Interest Expenses figures came in at $3.3 million (Q4 2025), $3.3 million (Q3 2025), and $3.7 million (Q2 2025), per Business Quant data.

Peer Comparison